ArticlePloS one2013
Autonomic test by EZSCAN in the screening for prediabetes and diabetes.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EZSCAN for undiagnosed type 2 diabetes mellitus: A systematic review and meta-analysis.PloS one · 2017Pooled it
- The Importance of Evaluating Sudomotor Function in the Diagnosis of Cardiac Autonomic Neuropathy.Cureus · 2024Article
- Multimodal testing reveals subclinical neurovascular dysfunction in prediabetes, challenging the diagnostic threshold of diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2023Article
- Time in range, especially overnight time in range, is associated with sudomotor dysfunction in patients with type 1 diabetes.Diabetology & metabolic syndrome · 2021Article
- Early Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres.Diagnostics (Basel, Switzerland) · 2021Review
- Assessment of sudomotor function in hypertensive with/without type-2 diabetes patients using SUDOSCAN: An electrophysiological study.Clinical neurophysiology practice · 2021Article
- A formula based on autonomic test using EZSCAN and anthropometric data for diagnosis of DM in China.Scientific reports · 2020Article
- Variability of electrochemical skin conductance for screening diabetes mellitus.Biomedical engineering letters · 2019Article
- Sudoscan is an effective screening method for asymptomatic diabetic neuropathy in Chinese type 2 diabetes mellitus patients.Journal of diabetes investigation · 2017Article
- Association of sudomotor function with peripheral artery disease in type 2 diabetes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- The Clinical Utility of SUDOSCAN in Chronic Kidney Disease in Chinese Patients with Type 2 Diabetes.PloS one · 2015Article
- Association of EZSCAN values with arterial stiffness in individuals without diabetes or cardiovascular disease.PloS one · 2014Article
- Distal Sensorimotor Neuropathy: Improvements in Diagnosis.The review of diabetic studies : RDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutonomic neuropathy is common in diabetics and may occur in prediabetes. A new and noninvasive autonomic test-EZSCAN evaluates sudomotor function precisely. No generally accepted EZSCAN thresholds to screen for prediabetes and diabetes have been defined. METHODOLOGY AND PRINCIPAL
findingsCross-sectional study of 5, 824 Chinese adults aged 40 and older was conducted in Shanghai, China. We used EZSCAN to evaluate autonomic function in different glucose status and screen for prediabetes and diabetes. The prevalence of prediabetes and diabetes were 21.9% and 17.5% respectively. Compared with the lowest quintile, the highest quintile of EZSCAN value had odds ratios for having dysglycemia (prediabetes or diabetes) of 2.08 (95% CI 1.67-2.58) in total population, 2.89 (95% CI 2.06-4.05) in men and 1.70 (95% CI 1.28-2.25) in women after adjustment for confounding factors. EZSCAN value improved the areas under ROC curve for detection of dysglycemia or diabetes beyond the contribution of conventional risk factors by 0.8% and 12.9%. The cut-off point of EZSCAN value higher than 30% provided reasonable sensitivities (70.3-83.7%) to detect dysglycemia not only in total population regardless of sex but also in individuals with high risk of developing diabetes. CONCLUSIONS AND SIGNIFICANCE: EZSCAN value higher than 30% indicate an increased risk of prevalent prediabetes and diabetes, suggesting that subjects with EZSCAN ≥30% should be further evaluated by oral glucose tolerance test. The improvement of EZSCAN for diabetes detection was still of limited clinical relevance. Thus the clinical application value of EZSCAN is needed to be explored in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.